There was no significant difference in the erythropoietin dosages used for patients in the two cohorts according to diabetes status in either cohort (diabetes vs no diabetes median 10,726 U vs 10,525 U, P=.09 in cohort 1; 12,254 U vs 12,310 U, P=.17 in cohort 2). The gene discussed is EPO; the disease is diabetes mellitus.